Table S1: Survey Data- Comparison by region

		Total	Comparison by Region*					
Question	**Categories**	**(N=175)**	**Aus/NZ (N=13)**	**Europe (N=40)**	**Latin America (N=12)**	**North America (N=97)**	**Other (N=13)**	**p value**
Did your center use low-dose acyclovir in allogeneic transplant recipients who were VZV+ or HSV+?	No	33 (18.9%)	4 (30.8%)	11 (27.5%)	1 (8.3%)	11 (11.3%)	6 (46.2%)	0.006
	Yes	142 (81.1%)	9 (69.2%)	29 (72.5%)	11 (91.7%)	86 (88.7%)	7 (53.8%)	
Indicate the low-dose acyclovir prophylactic treatment strategy used in VZV+ patients	Do not Treat	34 (23.9%)	3 (33.3%)	3 (10.3%)	3 (27.3%)	25 (29.1%)	0 (0.0%)	0.008
	Other duration	30 (21.1%)	1 (11.1%)	6 (20.7%)	0 (0.0%)	21 (24.4%)	2 (28.6%)	
	Treat for 12 months	27 (19.0%)	1 (11.1%)	0 (0.0%)	2 (18.2%)	24 (27.9%)	0 (0.0%)	
	Treat for 3 to 4 months	33 (23.2%)	2 (22.2%)	13 (44.8%)	3 (27.3%)	11 (12.8%)	4 (57.1%)	
	Treat until engraftment	18 (12.7%)	2 (22.2%)	7 (24.1%)	3 (27.3%)	5 (5.8%)	1 (14.3%)	
Indicate the low-dose acyclovir prophylactic treatment strategy used in HSV+ patients- (VZV -)	Do not Treat	2 (1.4%)	0 (0.0%)	0 (0.0%)	1 (9.1%)	1 (1.2%)	0 (0.0%)	0.017**
	Other duration	34 (23.9%)	1 (11.1%)	6 (20.7%)	0 (0.0%)	26 (30.2%)	1 (14.3%)	
	Treat for 12 months	24 (16.9%)	1 (11.1%)	0 (.%)	2 (18.2%)	21 (24.4%)	0 (.%)	
	Treat for 3 to 4 months	44 (31.0%)	3 (33.3%)	13 (44.8%)	4 (36.4%)	20 (23.3%)	4 (57.1%)	
	Treat until engraftment	38 (26.8%)	4 (44.4%)	10 (34.5%)	4 (36.4%)	18 (20.9%)	2 (28.6%)	
Did your center use prophylactic high-dose acyclovir in allogeneic	No	120 (68.6%)	8 (61.5%)	21 (52.5%)	7 (58.3%)	74 (76.3%)	10 (76.9%)	0.063

transplant recipients who were CMV+?	Yes	55 (31.4%)	5 (38.5%)	19 (47.5%)	5 (41.7%)	23 (23.7%)	3 (23.1%)	
Indicate the prophylactic high-dose acyclovir treatment strategy used in CMV + transplant recipients	Other duration	10 (18.2%)	1 (20.0%)	3 (15.8%)	0 (.%)	5 (22.7%)	1 (25.0%)	0.005
	Treat for 12 months	7 (12.7%)	0 (.%)	0 (.%)	0 (.%)	6 (27.3%)	1 (25.0%)	
	Treat for 3 to 4 months	22 (40.0%)	4 (80.0%)	11 (57.9%)	4 (80.0%)	2 (9.1%)	1 (25.0%)	
	Treat until engraftment	16 (29.1%)	0 (.%)	5 (26.3%)	1 (20.0%)	9 (40.9%)	1 (25.0%)	
Did your center use a strategy of routine ganciclovir prophylaxis in some transplant recipients?	No	126 (72.4%)	6 (46.2%)	30 (75.0%)	8 (66.7%)	75 (78.1%)	7 (53.8%)	0.069
	Yes	48 (27.6%)	7 (53.8%)	10 (25.0%)	4 (33.3%)	21 (21.9%)	6 (46.2%)	
When was prophylaxis initiated?	At time of engraftment	26 (53.1%)	2 (28.6%)	7 (70.0%)	2 (50.0%)	13 (61.9%)	2 (28.6%)	0.446
	Other initiation schedule	10 (20.4%)	2 (28.6%)	1 (10.0%)	0 (.%)	4 (19.0%)	3 (42.9%)	
	Pre-transplantation	13 (26.5%)	3 (42.9%)	2 (20.0%)	2 (50.0%)	4 (19.0%)	2 (28.6%)	
What was the duration of ganciclovir prophylaxis?	Greater than 3 months but less than or equal to 6	8 (16.3%)	1 (14.3%)	1 (10.0%)	1 (25.0%)	4 (19.0%)	1 (14.3%)	0.735
	Less than or equal to 3 months	36 (73.5%)	6 (85.7%)	9 (90.0%)	3 (75.0%)	14 (66.7%)	4 (57.1%)	
	Other duration	5 (10.2%)	0 (.%)	0 (.%)	0 (.%)	3 (14.3%)	2 (28.6%)	
Did your center use a strategy of surveillance and preemptive therapy in at least some transplant recipients?	No	16 (9.2%)	4 (30.8%)	2 (5.0%)	2 (16.7%)	5 (5.2%)	3 (23.1%)	0.007
	Yes	158 (90.8%)	9 (69.2%)	38 (95.0%)	10 (83.3%)	91 (94.8%)	10 (76.9%)	

Please indicate the primary means of surveillance used.	CMV antigenemia (pp65)	72 (45.3%)	3 (33.3%)	16 (42.1%)	6 (60.0%)	40 (44.0%)	7 (63.6%)	0.725
	Other method	7 (4.4%)	0 (.%)	2 (5.3%)	0 (.%)	4 (4.4%)	1 (9.1%)	
	Plasma CMV-DNA PCR	45 (28.3%)	3 (33.3%)	8 (21.1%)	2 (20.0%)	30 (33.0%)	2 (18.2%)	
	Whole blood or leukocyte CMV-DNA PCR	35 (22.0%)	3 (33.3%)	12 (31.6%)	2 (20.0%)	17 (18.7%)	1 (9.1%)	
Which transplant recipients underwent routine surveillance?	All recipients regardless of CMV serologic status	98 (61.6%)	5 (55.6%)	31 (81.6%)	9 (90.0%)	46 (50.5%)	7 (63.6%)	<.001
	CMV seropositive recipients (D+/R+ and D-/R+)	57 (35.8%)	4 (44.4%)	5 (13.2%)	1 (10.0%)	44 (48.4%)	3 (27.3%)	
	Only CMV seropositive recipients (D+/R+ and D-/R+)	3 (1.9%)	0 (.%)	2 (5.3%)	0 (0.0%)	1 (1.1%)	0 (.%)	
	Other surveillance strategy	1 (0.6%)	0 (.%)	0 (.%)	0 (.%)	0 (.%)	1 (9.1%)	
How often were surveillance studies administered in the first 10 days post-transplant?	Other routine	8 (5.0%)	0 (.%)	4 (10.5%)	0 (.%)	2 (2.2%)	2 (18.2%)	0.158
	Twice per month	8 (5.0%)	0 (.%)	1 (2.6%)	1 (10.0%)	5 (5.5%)	1 (9.1%)	
	Weekly or more frequently	143 (89.9%)	9 (100%)	33 (86.8%)	9 (90.0%)	84 (92.3%)	8 (72.7%)	
If CMV was detected by surveillance, how long were patients usually treated?	2-3 weeks	14 (8.9%)	0 (.%)	2 (5.3%)	1 (10.0%)	10 (11.0%)	1 (10.0%)	0.593
	2-3 weeks, or until clearance of CMV antigen or DNA	90 (57.0%)	7 (77.8%)	25 (65.8%)	8 (80.0%)	44 (48.4%)	6 (60.0%)	
	Other length of treatment	12 (7.6%)	0 (.%)	1 (2.6%)	0 (.%)	10 (11.0%)	1 (10.0%)	
	Until clearance of CMV antigen or DNA	25 (15.8%)	2 (22.2%)	8 (21.1%)	0 (.%)	13 (14.3%)	2 (20.0%)	
	Until day 100 after transplant	17 (10.8%)	0 (.%)	2 (5.3%)	1 (10.0%)	14 (15.4%)	0 (.%)	

Did your center use a prophylactic or preemptive approach to CMV in high-risk transplant recipients after day	No	52 (29.9%)	3 (23.1%)	8 (20.0%)	4 (33.3%)	31 (32.3%)	6 (46.2%)	0.385
	Yes	122 (70.1%)	10 (76.9%)	32 (80.0%)	8 (66.7%)	65 (67.7%)	7 (53.8%)	
Inidicate the primary strategy used in high-risk recipients after day 100.	Antiviral prophylaxis with high-dose valacyclovir	4 (3.3%)	1 (10.0%)	1 (3.1%)	0 (.%)	2 (3.1%)	0 (.%)	0.611
	Antiviral prophylaxis with oral valgancyclovir	2 (1.6%)	0 (.%)	0 (.%)	0 (.%)	1 (1.5%)	1 (14.3%)	
	Other strategy	6 (4.9%)	0 (.%)	0 (.%)	0 (.%)	6 (9.2%)	0 (.%)	
	Treatment of disease	14 (11.5%)	1 (10.0%)	4 (12.5%)	0 (.%)	8 (12.3%)	1 (14.3%)	
	Virologic surveillance/ preemptive therapy	96 (78.7%)	8 (80.0%)	27 (84.4%)	8 (100%)	48 (73.8%)	5 (71.4%)	
If surveillance was used after day 100, how often were surveillance tests administered?	Other routine	22 (18.8%)	1 (10.0%)	6 (18.8%)	0 (.%)	13 (21.3%)	2 (33.3%)	0.706
	Twice per month	61 (52.1%)	5 (50.0%)	17 (53.1%)	5 (62.5%)	30 (49.2%)	4 (66.7%)	
	Weekly or more frequently	34 (29.1%)	4 (40.0%)	9 (28.1%)	3 (37.5%)	18 (29.5%)	0 (.%)	
Did your center have a strategy for using CMV seronegative blood products and/or leukoreduction in allogeneic	No	12 (6.9%)	0 (.%)	2 (5.0%)	0 (.%)	6 (6.3%)	4 (30.8%)	0.045
	Yes	162 (93.1%)	13 (100%)	38 (95.0%)	12 (100%)	90 (93.8%)	9 (69.2%)	
Indicate your center's primary strategy.	Both CMV seronegative blood products and leukoreduction	60 (37.0%)	2 (15.4%)	16 (42.1%)	2 (16.7%)	38 (42.2%)	2 (22.2%)	0.097
	CMV seronegative blood products ONLY	10 (6.2%)	3 (23.1%)	1 (2.6%)	0 (.%)	6 (6.7%)	0 (.%)	
	Either, CMV seronegative blood products preferred	34 (21.0%)	7 (53.8%)	5 (13.2%)	1 (8.3%)	18 (20.0%)	3 (33.3%)	
	Either, no preference	4 (2.5%)	0 (.%)	0 (.%)	1 (8.3%)	3 (3.3%)	0 (.%)	

	Leukoreduction ONLY	48 (29.6%)	1 (7.7%)	14 (36.8%)	8 (66.7%)	22 (24.4%)	3 (33.3%)	
	Other Strategy	6 (3.7%)	0 (.%)	2 (5.3%)	0 (.%)	3 (3.3%)	1 (11.1%)	
Indicate which patients received CMV-seronegative blood products and/or leukoreductions.	All patients	76 (46.9%)	3 (23.1%)	21 (55.3%)	7 (58.3%)	40 (44.4%)	5 (55.6%)	0.071
	Only CMV D-/R-	39 (24.1%)	5 (38.5%)	12 (31.6%)	1 (8.3%)	18 (20.0%)	3 (33.3%)	
	Other patient groups	6 (3.7%)	0 (.%)	1 (2.6%)	0 (.%)	4 (4.4%)	1 (11.1%)	
	CMV D-/R- and D+/R-	41 (25.3%)	5 (38.5%)	4 (10.5%)	4 (33.3%)	28 (31.1%)	0 (.%)	
Did your center ever use adoptive immunotherapy in allogeneic transplant recipients?	No	167 (96.0%)	13 (100%)	38 (95.0%)	12 (100%)	92 (95.8%)	12 (92.3%)	0.9
	Yes	7 (4.0%)	0 (.%)	2 (5.0%)	0 (.%)	4 (4.2%)	1 (7.7%)	
Indicate your center's primary strategy for using adoptive immunotherapy.	Only after failure of preemptive therapy	4 (57.1%)	0 (.%)	1 (50.0%)	0 (.%)	2 (50.0%)	1 (100%)	1
	Used as preemptive therapy	2 (28.6%)	0 (.%)	1 (50.0%)	0 (.%)	1 (25.0%)	0 (.%)	
	Used as prophylaxis	1 (14.3%)	0 (.%)	0 (.%)	0 (.%)	1 (25.0%)	0 (.%)	
Did your center use systemic antifungal prophylaxis in allogeneic transplant recipients?	No	19 (10.9%)	0 (.%)	9 (22.5%)	0 (.%)	6 (6.3%)	4 (30.8%)	0.005
	Yes	155 (89.1%)	13 (100%)	31 (77.5%)	12 (100%)	90 (93.8%)	9 (69.2%)	
Indicate when your center initiated antifungal prophylaxis.	With conditioning regimen	97 (62.6%)	9 (69.2%)	25 (80.7%)	9 (75.0%)	49 (54.4%)	5 (55.6%)	0.007
	At infusion of graft (Day 0 +/- 1 day)	42 (27.1%)	4 (30.8%)	1 (3.2%)	2 (16.7%)	33 (36.7%)	2 (22.2%)	

	Other	16 (10.3%)	0 (.%)	5 (16.1%)	1 (8.3%)	8 (8.9%)	2 (22.2%)	
Indicate the duration of antifungal prophylaxis used by your center.	Treat until engraftment	35 (22.7%)	3 (23.1%)	8 (25.8%)	3 (25.0%)	15 (16.9%)	6 (66.7%)	0.116
	Treat until day 75-100	74 (48.1%)	8 (61.5%)	16 (51.6%)	6 (75.0%)	42 (47.2%)	2 (22.2%)	
	Other	45 (29.2%)	2 (15.3%)	7 (22.6%)	3 (25.0%)	32 (36.0%)	1 (11.1%)	
Indicate the primary drug used for systemic antifungal prophylaxis at your center.	Fluconazole	124 (80.5%)	11 (84.6%)	21 (67.7%)	12 (100%)	73 (82.2%)	7 (77.8%)	0.098
	Itraconazole	18 (11.69%	1 (7.7%)	9 (29.3%)	0 (.%)	7 (7.9%)	1 (11.1%)	
	Other	12 (7.8%)	1 (7.7%)	1 (3.2%)	0 (.%)	9 (10.1%)	1 (11.1%)	

* Countries represented by region (number of responding programs): US/Can--United States (90), Canada (7); Europe-- Germany (13)United Kingdom (7), Spain (5), Belgium (3), Sweden (2), Finland (2), Italy (2), Switzerland (1), Norway (1), Denmark (1), Poland (1), Portugal (1), Czech Republic (1); Australia/NZ-- Australia (10), New Zealand (3); Latin America-- Brazil (3), Argentina (3), Uruguay (3), Venezuela (2), Mexico (1); Middle East-- Israel (2), Iran (1), Pakistan (1); Asia-- India (2), China, Hong Kong (1), Japan (1), Taiwan (1), Korea (1); Africa-- South Africa (3)

**P value for comparison only between those regions that treated until engraftment, 3-4 months, and 12 months only.

Table S2: Survey data- Comparison by patient population and center size

		Patient Population				Center Size		
Question	**Categories**	**Both adult and pediatric patients (N=57)**	**Adult patients only (N=81)**	**Pediatric patients only (N=37)**	**p value**	**≤ 50 annual trans-plants (N=108)**	**> 50 annual trans-plants (N=56)**	**p value**
Did your center use low-dose acyclovir in allogeneic transplant recipients who were VZV+ or HSV+?	No	11 (19.3%)	15 (18.5%)	7 (18.9%)	1	16 (14.8%)	14 (25.0%)	0.11
	Yes	46 (80.7%)	66 (81.5%)	30 (81.1%)		92 (85.2%)	42 (75.0%)	
Indicate the low-dose acyclovir prophylactic treatment strategy used in VZV+ patients	Do not Treat	14 (30.4%)	12 (18.2%)	8 (26.7%)	0.727	25 (27.2%)	7 (16.7%)	0.534
	Other duration	7 (15.2%)	17 (25.8%)	6 (20.0%)		16 (17.4%)	10 (23.8%)	
	Treat for 12 months	8 (17.4%)	14 (21.2%)	5 (16.7%)		19 (20.7%)	8 (19.0%)	
	Treat for 3 to 4 months	13 (28.3%)	13 (19.7%)	7 (23.3%)		23 (25.0%)	10 (23.8%)	
	Treat until engraftment	4 (8.7%)	10 (15.2%)	4 (13.3%)		9 (9.8%)	7 (16.7%)	
Indicate the low-dose acyclovir prophylactic treatment strategy used in HSV+ patients- (VZV -)	Do not Treat	0 (.%)	1 (1.5%)	1 (3.3%)	0.839	2 (2.2%)	0 (.%)	0.688
	Other duration	10 (21.7%)	17 (25.8%)	7 (23.3%)		20 (21.7%)	10 (23.8%)	
	Treat for 12 months	7 (15.2%)	14 (21.2%)	3 (10.0%)		16 (17.4%)	7 (16.7%)	
	Treat for 3 to 4 months	15 (32.6%)	18 (27.3%)	11 (36.7%)		32 (34.8%)	11 (26.2%)	

	Treat until engraftment	14 (30.4%)	16 (24.2%)	8 (26.7%)		22 (23.9%)	14 (33.3%)	
Did your center use prophylactic high-dose acyclovir in allogeneic transplant recipients who were CMV+?	No	40 (70.2%)	63 (77.8%)	17 (45.9%)	0.002	73 (67.6%)	38 (67.9%)	0.973
	Yes	17 (29.8%)	18 (22.2%)	20 (54.1%)		35 (32.4%)	18 (32.1%)	
Indicate the prophylactic high-dose acyclovir treatment strategy used in CMV + transplant recipients	Other duration	2 (11.1%)	4 (23.5%)	4 (20.0%)	0.746	6 (16.7%)	4 (22.2%)	0.098
	Treat for 12 months	2 (11.1%)	2 (11.8%)	3 (15.0%)		2 (5.6%)	5 (27.8%)	
	Treat for 3 to 4 months	6 (33.3%)	8 (47.1%)	8 (40.0%)		15 (41.7%)	6 (33.3%)	
	Treat until engraftment	8 (44.4%)	3 (17.6%)	5 (25.0%)		13 (36.1%)	3 (16.7%)	
Did your center use a strategy of routine ganciclovir prophylaxis in some transplant recipients?	No	39 (68.4%)	57 (71.3%)	30 (81.1%)	0.393	81 (75.0%)	39 (69.6%)	0.463
	Yes	18 (31.6%)	23 (28.8%)	7 (18.9%)		27 (25.0%)	17 (30.4%)	
When was prophylaxis initiated?	At time of engraftment	11 (57.9%)	12 (52.2%)	3 (42.9%)	0.854	15 (53.6%)	9 (52.9%)	0.921
	Other initiation schedule	4 (21.1%)	5 (21.7%)	1 (14.3%)		5 (17.9%)	4 (23.5%)	
	Pre-transplantation	4 (21.1%)	6 (26.1%)	3 (42.9%)		8 (28.6%)	4 (23.5%)	
What was the duration of ganciclovir prophylaxis?	Greater than 3 months but less than or equal to 6	3 (15.8%)	4 (17.4%)	1 (14.3%)	0.758	6 (21.4%)	2 (11.8%)	0.885
	Less than or equal to 3 months	13 (68.4%)	18 (78.3%)	5 (71.4%)		19 (67.9%)	13 (76.5%)	
	Other duration	3 (15.8%)	1 (4.3%)	1 (14.3%)		3 (10.7%)	2 (11.8%)	

Did your center use a strategy of surveillance and preemptive therapy in at least some transplant recipients?	No	5 (8.8%)	7 (8.8%)	4 (10.8%)	0.889	12 (11.1%)	3 (5.4%)	0.268
	Yes	52 (91.2%)	73 (91.3%)	33 (89.2%)		96 (88.9%)	53 (94.6%)	
Please indicate the primary means of surveillance used.	CMV antigenemia (pp65)	27 (50.9%)	30 (41.1%)	15 (45.5%)	0.544	44 (45.4%)	23 (43.4%)	0.97
	Other method	2 (3.8%)	4 (5.5%)	1 (3.0%)		4 (4.1%)	3 (5.7%)	
	Plasma CMV-DNA PCR	12 (22.6%)	20 (27.4%)	13 (39.4%)		27 (27.8%)	15 (28.3%)	
	Whole blood or leukocyte CMV-DNA PCR	12 (22.6%)	19 (26.0%)	4 (12.1%)		22 (22.7%)	12 (22.6%)	
Which transplant recipients underwent routine surveillance?	All recipients regardless of CMV serologic status	34 (64.2%)	41 (56.2%)	23 (69.7%)	0.649	56 (57.7%)	38 (71.7%)	0.104
	CMV seropositive recipients (D+/R+ and D-/R+)	17 (32.1%)	30 (41.1%)	10 (30.3%)		39 (40.2%)	13 (24.5%)	
	Only CMV seropositive recipients (D+/R+ and D-/R+)	1 (1.9%)	2 (2.7%)	0 (.%)		1 (1.0%)	2 (3.8%)	
	Other surveillance strategy	1 (1.9%)	0 (0.0%)	0 (.%)		1 (1.0%)	0 (.%)	
How often were surveillance studies administered in the first 10 days post-transplant?	Other routine	2 (3.8%)	4 (5.5%)	2 (6.1%)	0.945	5 (5.2%)	2 (3.8%)	0.834
	Twice per month	3 (5.7%)	3 (4.1%)	2 (6.1%)		6 (6.2%)	2 (3.8%)	
	Weekly or more frequently	48 (90.6%)	66 (90.4%)	29 (87.9%)		86 (88.7%)	49 (92.5%)	
If CMV was detected by surveillance, how long were patients usually treated?	2-3 weeks	4 (7.7%)	8 (11.0%)	2 (6.1%)	0.84	5 (5.2%)	9 (17.0%)	0.117
	2-3 weeks, or until clearance of CMV antigen or DNA	26 (50.0%)	45 (61.6%)	19 (57.6%)		59 (61.5%)	25 (47.2%)	
	Other length of treatment	6 (11.5%)	4 (5.5%)	2 (6.1%)		6 (6.3%)	6 (11.3%)	

	Until clearance of CMV antigen or DNA	10 (19.2%)	9 (12.3%)	6 (18.2%)		15 (15.6%)	8 (15.1%)	
	Until day 100 after transplant	6 (11.5%)	7 (9.6%)	4 (12.1%)		11 (11.5%)	5 (9.4%)	
Did your center use a prophylactic or preemptive approach to CMV in high-risk transplant recipients after day	No	22 (38.6%)	19 (23.8%)	11 (29.7%)	0.174	30 (27.8%)	17 (30.4%)	0.729
	Yes	35 (61.4%)	61 (76.3%)	26 (70.3%)		78 (72.2%)	39 (69.6%)	
Inidicate the primary strategy used in high-risk recipients after day 100.	Antiviral prophylaxis with high-dose valacyclovir	1 (2.9%)	3 (4.9%)	0 (.%)	0.921	3 (3.8%)	1 (2.6%)	0.07
	Antiviral prophylaxis with oral valgancyclovir	0 (.%)	1 (1.6%)	1 (3.8%)		2 (2.6%)	0 (.%)	
	Other strategy	1 (2.9%)	4 (6.6%)	1 (3.8%)		2 (2.6%)	3 (7.7%)	
	Treatment of disease	3 (8.6%)	8 (13.1%)	3 (11.5%)		13 (16.7%)	1 (2.6%)	
	Virologic surveillance/ preemptive therapy	30 (85.7%)	45 (73.8%)	21 (80.8%)		58 (74.4%)	34 (87.2%)	
If surveillance was used after day 100, how often were surveillance tests administered?	Other routine	5 (14.7%)	13 (22.0%)	4 (16.7%)	0.539	15 (20.3%)	7 (18.4%)	0.897
	Twice per month	17 (50.0%)	33 (55.9%)	11 (45.8%)		37 (50.0%)	21 (55.3%)	
	Weekly or more frequently	12 (35.3%)	13 (22.0%)	9 (37.5%)		22 (29.7%)	10 (26.3%)	
Did your center have a strategy for using CMV seronegative blood products and/or leukoreduction in allogeneic	No	8 (14.0%)	2 (2.5%)	2 (5.4%)	0.035	7 (6.5%)	5 (8.9%)	0.546
	Yes	49 (86.0%)	78 (97.5%)	35 (94.6%)		101 (93.5%)	51 (91.1%)	
Indicate your center's primary strategy.	Both CMV seronegative blood products and leukoreduction	14 (28.6%)	36 (46.2%)	10 (28.6%)	0.016	35 (34.7%)	22 (43.1%)	0.659

	CMV seronegative blood products ONLY	0 (.%)	7 (9.0%)	3 (8.6%)		7 (6.9%)	2 (3.9%)	
	Either, CMV seronegative blood products preferred	13 (26.5%)	13 (16.7%)	8 (22.9%)		21 (20.8%)	10 (19.6%)	
	Either, no preference	0 (.%)	2 (2.6%)	2 (5.7%)		3 (3.0%)	1 (2.0%)	
	Leukoreduction ONLY	19 (38.8%)	17 (21.8%)	12 (34.3%)		33 (32.7%)	13 (25.5%)	
	Other Strategy	3 (6.1%)	3 (3.8%)	0 (.%)		2 (2.0%)	3 (5.9%)	
Indicate which patients received CMV-seronegative blood products and/or leukoreductions.	All patients	26 (53.1%)	28 (35.9%)	22 (62.9%)	0.068	46 (45.5%)	26 (51.0%)	0.739
	Only CMV D-/R-	9 (18.4%)	24 (30.8%)	6 (17.1%)		23 (22.8%)	13 (25.5%)	
	Other patient groups	0 (.%)	5 (6.4%)	1 (2.9%)		4 (4.0%)	2 (3.9%)	
	CMV D-/R- and D+/R-	14 (28.6%)	21 (26.9%)	6 (17.1%)		28 (27.7%)	10 (19.6%)	
Did your center ever use adoptive immunotherapy in allogeneic transplant recipients?	No	53 (93.0%)	79 (98.8%)	35 (94.6%)	0.197	105 (97.2%)	53 (94.6%)	0.412
	Yes	4 (7.0%)	1 (1.3%)	2 (5.4%)		3 (2.8%)	3 (5.4%)	
Indicate your center's primary strategy for using adoptive immunotherapy.	Only after failure of preemptive therapy	3 (75.0%)	0 (.%)	1 (50.0%)	0.429	2 (66.7%)	1 (33.3%)	1
	Used as preemptive therapy	0 (.%)	1 (100.0%	1 (50.0%)		1 (33.3%)	1 (33.3%)	
	Used as prophylaxis	1 (25.0%)	0 (.%)	0 (.%)		0 (.%)	1 (33.3%)	
Did your center use systemic antifungal prophylaxis in allogeneic transplant recipients?	No	6 (10.5%)	12 (15.0%)	1 (2.7%)	0.129	9 (8.3%)	10 (17.9%)	0.078
	Yes	51 (89.5%	68 (85.0%)	36 (97.3%)		99 (91.7%)	46 (82.1%)	

Indicate when your center initiated antifungal prophylaxis.	With conditioning regimen	36 (70.6%)	34 (50.0%)	27 (75.0%)	0.048	66 (66.7%)	25 (54.3%)	0.329
	At infusion of graft (Day 0 +/- 1d)	9 (17.7%)	26 (38.2%)	7 (19.4%)		25 (25.3%)	15 (32.6%)	
	Other	6 (11.8%)	8 (11.8%)	2 (5.6%)		8 (8.1%)	6 (13.0%)	
Indicate the duration of antifungal prophylaxis used by your center.	Treat until engraftment	11 (22.0%)	17 (25.0%)	7 (19.4%)	0.664	21 (21.2%)	11 (24.4%)	0.651
	Treat until day 75-100	26 (52.0%)	28 (41.2%)	20 (55.6%)		52 (52.5%)	20 (44.4%)	
	Other	13 (26.0%)	23 (33.8%)	9 (25.0%)		26 (26.3%)	14 (31.1%)	
Indicate the primary drug used for systemic antifungal prophylaxis at your center.	Fluconazole	42 (84.0%)	53 (77.9%)	29 (80.6%)	0.886	81 (81.8%)	34 (75.6%)	0.6
	Itraconazole	5 (10.0%)	8 (11.8%)	18 (11.7%)		11 (11.1%)	7 (15.6%)	
	Other	3 (6.0%)	7 (10.3%)	12 (7.8%)		7 (7.1%)	4 (8.9%)	